8-K: Journey Medical Establishes New At-The-Market Equity Offering

Journey Medical Corporation has entered into a new At Market Issuance Sales Agreement to potentially sell up to 3,750,000 shares of common stock, replacing a prior agreement.

Summary

• Journey Medical Corporation entered into a new At Market Issuance Sales Agreement on August 28, 2025, with B. Riley Securities, Inc. and Lake Street Capital Markets, LLC.
• The company may offer and sell, at its sole discretion, up to 3,750,000 shares of its common stock through these agents.
• Sales will be conducted as "at the market" offerings, allowing for flexible capital raising.
• The company will pay each agent a commission of 3.0% of the gross proceeds from the sales of shares.
• The previous At Market Issuance Sales Agreement, dated December 30, 2022, with B. Riley Securities, Inc. was terminated on August 28, 2025.
• Under the terminated agreement, 4,121,318 shares of common stock were sold from December 30, 2022, to August 28, 2025.

Sentiment

Score: 6

Explanation: The establishment of a new ATM facility provides financial flexibility and access to capital, which is generally positive for a company. However, it also introduces potential dilution for existing shareholders, leading to a moderately positive sentiment rather than strongly positive.

Positives

• Provides a flexible and efficient mechanism for raising capital as needed, without the immediate dilutive impact of a large, single offering.
• Allows access to public markets through established agents, potentially reducing the time and cost associated with traditional underwritten offerings.
• Diversifies sales agents by adding Lake Street Capital Markets, LLC alongside B. Riley Securities, Inc., potentially broadening market reach.
• The company retains sole discretion over the timing, price, and volume of share sales, enabling strategic capital deployment.

Negatives

• Potential for significant dilution of existing shareholders if all 3,750,000 shares are sold under the new agreement.
• The "at the market" nature of the offering could create an overhang on the stock price due to the potential for future sales.
• Commissions of 3.0% of gross proceeds and reimbursement of certain expenses to agents will reduce the net proceeds received by the company.

Risks

• There is no assurance that the agents will be successful in selling Placement Shares, impacting the company's ability to raise capital.
• The company's ability to raise capital is subject to prevailing market conditions and its common stock price.
• Enforceability of the Sales Agreement may be limited by bankruptcy, insolvency, reorganization, moratorium, or similar laws affecting creditors' rights generally, and by general equitable principles.
• Indemnification and contribution provisions within the agreement may be limited by federal or state securities laws and public policy considerations.
• Risk of stop orders from the SEC or other governmental authorities suspending the effectiveness of the registration statement for the shares.
• Potential for suspension of trading or delisting of the common stock from the Nasdaq Capital Market.
• Material adverse changes in financial markets, outbreaks of hostilities, or other calamities could make it impracticable or inadvisable to market the Placement Shares.
• Disruption of securities settlements or clearance services in the United States could hinder transactions.
• A banking moratorium declared by U.S. Federal or New York authorities could impact the ability to complete sales.

Future Outlook

The company now has a mechanism in place to raise up to 3,750,000 shares of common stock, providing ongoing financial flexibility to fund operations or strategic initiatives at its discretion, subject to market conditions.

Industry Context

At-the-market (ATM) offerings are a common and flexible capital-raising tool for publicly traded companies, particularly in the biotechnology and pharmaceutical sectors, to access equity markets efficiently. This allows companies to raise capital incrementally, reducing the immediate dilutive impact compared to a large, single offering and providing funding for ongoing research, development, or commercialization efforts.

Stakeholder Impact

• Shareholders: Potential for dilution as new shares are issued, which could impact earnings per share and ownership percentage. The market price of shares could also be affected by the ongoing offering.
• Company: Enhanced financial flexibility and access to capital for general corporate purposes, working capital, or strategic initiatives without the need for a large, single offering.
• Agents (B. Riley Securities, Inc. and Lake Street Capital Markets, LLC): Will earn commissions (3.0% of gross proceeds) for facilitating share sales, benefiting from the transaction.

Next Steps

• The company may, at its discretion, issue and sell shares of common stock through the appointed agents into the market.
• Agents will use commercially reasonable efforts to sell shares based on company instructions, including any price, time, or size limits.
• The company will file prospectus supplements with the SEC detailing sales made under the agreement as required by the Securities Act.

Key Dates

Keywords

Journey Medical Corporation, DERM, At Market Issuance, ATM Offering, Equity Offering, Capital Raise, Common Stock, SEC Filing, Form 8-K, B. Riley Securities, Lake Street Capital Markets, Dilution, Nasdaq Capital Market